Skip to main navigation Skip to search Skip to main content

Merkel Cell Carcinoma, Version 1.2018

  • Christopher K. Bichakjian
  • , Thomas Olencki
  • , Sumaira Z. Aasi
  • , Murad Alam
  • , James S. Andersen
  • , Rachel Blitzblau
  • , Glen M. Bowen
  • , Carlo M. Contreras
  • , Gregory A. Daniels
  • , Roy Decker
  • , Jeffrey M. Farma
  • , Kris Fisher
  • , Brian Gastman
  • , Karthik Ghosh
  • , Roy C. Grekin
  • , Kenneth Grossman
  • , Alan L. Ho
  • , Karl D. Lewis
  • , Manisha Loss
  • , Daniel D. Lydiatt
  • Jane Messina, Kishwer S. Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D. Schmults, Ashok R. Shaha, Valencia Thomas, Yaohui G. Xu, John A. Zic, Karin G. Hoffmann, Anita M. Engh
  • University of Michigan, Ann Arbor
  • Ohio State University
  • Stanford University
  • Northwestern University
  • City of Hope National Med Center
  • Duke University
  • University of Utah
  • University of Alabama at Birmingham
  • University of California at San Diego
  • Yale University
  • Fox Chase Cancer Center
  • University of Tennessee Health Science Center
  • Case Western Reserve University
  • Mayo Clinic Rochester, MN
  • University of California at San Francisco
  • Memorial Sloan-Kettering Cancer Center
  • University of Colorado Cancer Center
  • Johns Hopkins University
  • University of Nebraska Medical Center
  • Moffitt Cancer Center
  • Seattle Cancer Care Alliance
  • Dana-Farber/Brigham and Women's Cancer Center
  • University of Texas MD Anderson Cancer Center
  • University of Wisconsin-Madison
  • Vanderbilt University

Research output: Contribution to journal › Review article › peer-review

238 Scopus citations

Abstract

This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.

Original languageEnglish
Pages (from-to)742-774
Number of pages33
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Dive into the research topics of 'Merkel Cell Carcinoma, Version 1.2018'. Together they form a unique fingerprint.

Cite this